SecBot SecBot

IRD

Opus Genetics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001228627 Biotech & Drug Discovery
$3.26 −0.21 (−6.20%)
Oct 26 4:00 PM ET · prev $3.47
Market cap
$317.8M
Small cap
Consensus
Buy
95% Buy or better · 22 analysts
Median target
$13.00
+299% · range $8.00–20.00
Next earnings
Nov 10
in 15 days · EPS est. −$0.15
1 year
+62.8%
from $2.00 · Oct 27
30 days
−35.5%
from $5.05
52-week range
$1.74–6.07
−46% from high · low Nov 17
Avg volume 20D
1.70M
shares / day
Short interest
13.01M
≈15.6% of shares · +3.5%
Days to cover
6.0
at average volume
Insider net
−$10.7M
0 buyers · 7 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 4 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 4/9 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Opus Genetics presented positive interim clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $10.7M.

  • InstitutionsBULLISH

    Q2 2026: 16 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    21 of 22 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.158 → −$0.152 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.5% to 13.01M shares. 6.0 days to cover, ≈15.6% of shares.

  • TrendDOWNTREND

    28% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED3,116,487$12.8M
GOLDMAN SACHS GROUP INCDOUBLED1,527,229$6.3M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,367,712$5.6M
STATE STREET CORPDOUBLED790,136$3.2M
UBS Group AGDOUBLED683,895$2.8M
CITADEL ADVISORS LLCDOUBLED665,662$2.7M
MORGAN STANLEYDOUBLED464,900$1.9M
NORTHERN TRUST CORPDOUBLED442,154$1.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

22 analysts
Buy 95% rate it Buy or better
Strong Buy6Buy15Hold1Sell0Strong Sell0
12-month targets · 17 analysts

Price is below the lowest target. Median implies +299%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 22, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Oct 16, 2026Citizens
REITERATE
REITERATEMarket Outperform
Oct 6, 2026Jones Trading
MAINTAIN
MAINTAINBuy
Oct 2, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Sep 10, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Sep 9, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$10.7M
sold · 7 insiders
DateInsiderTypeValue
Sep 30, 2026
Foundation Fighting Blindness Retinal Degeneration Fund
Director
SELL$2.8M
Sep 9, 2026
Magrath George
Chief Executive Officer
EXERCISE$451.0K
Sep 9, 2026
Magrath George
Chief Executive Officer
TAX W/H$451.0K
Sep 8, 2026
Gallagher Cam
Director
EXERCISE$902.0K
Sep 3, 2026
Gagnon Robert E.
Chief Financial Officer
SELL$127.2K
Jul 23, 2026
Gagnon Robert E.
Chief Financial Officer
SELL$22.9K
Jul 23, 2026
Magrath George
Chief Executive Officer
SELL$27.9K
Jul 23, 2026
SCHACHLE JOSEPH K
Chief Operating Officer
SELL$13.7K

Earnings setup

Estimates
Nov 10
reports in 15 days
−$0.15
EPS estimate, this quarter
+3%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.15-$0.21–-$0.09+0.0%$2.1M
Next Q-$0.04-$0.19–$0.39+2.3%$8.2M
Current FY-$0.94-$1.24–-$0.28+0.2%$13.8M
Next FY-$0.71-$1.24–-$0.40+0.0%$13.6M

Short side

FINRA· Sep 30, 2026
13,013,222
shares short
+3.5%
vs prior settlement
6.0
days to cover
≈15.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
Benjamin R. Yerxa, an officer of Opus Genetics, filed a Form 144 notice of intent to sell 33,189 shares of common…
144 — Impact 2/10
Oct 21, 2026 SEC
Opus Genetics announced the transition of Chief Scientific and Development Officer Ashwath Jayagopal, effective…
8-K — Impact 2/10
Oct 17, 2026 FDA PDUFA
PDUFA: IRD — Phentolamine Ophthalmic Solution 0.75% in presbyopia — 2026-10-17
FDA target action date 2026-10-17 for IRD (Opus Genetics, Inc.). Drug: Phentolamine Ophthalmic Solut
Oct 15, 2026 SEC
Opus Genetics presented positive interim clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at…
8-K — Impact 6/10
Oct 15, 2026 Press
Opus Genetics presented interim clinical data at Retina in Rio 2026 for its two lead gene therapy programs. OPGx-BEST1…
Impact 6/10
Sep 30, 2026 Insider
Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 shares
Director @ $4.96 ($2.8M)
Sep 9, 2026 Insider
Magrath George acquired via exercise 392,157 shares
Chief Executive Officer @ $1.15 ($451.0K)
Sep 9, 2026 Insider
Magrath George surrendered for taxes 75,541 shares
Chief Executive Officer @ $5.97 ($451.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
IRD Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Oct 26, 2026
Clinical Trial
🔒 Fresh data, subscribers only
Oct 26, 2026
Clinical Trial
🔒 Fresh data, subscribers only
Oct 17, 2026
FDA decision date
PDUFA: IRD — Phentolamine Ophthalmic Solution 0.75% in presbyopia — 2026-10-17
FDA target action date 2026-10-17 for IRD (Opus Genetics, Inc.). Drug: Phentolamine Ophthalmic Solution 0.75%. Indication: presbyopia. FDA set a…
Oct 15, 2026
FDA
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026...
Oct 8, 2026
Clinical Trial
The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances
Phase 2 · COMPLETED

SecBot reports

20 filings · 5 press releases · 3 bullish · 3 bearish · 1 mixed · 13 neutral
All IRD filing & press-release reports (25)